Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015

[PR Newswire] – NORTH CHICAGO, Ill., Oct. 1, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical development … Read . . . → Read More: Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting Market Update (NYSE:ABBV): AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting Company Update (NYSE:ABBV): AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015